Can you survive BPDCN?

While BPDCN can occur at any age, the median age at diagnosis is in the mid-60s, with approximately 75% of cases occurring in men. Historically, initial response to combination chemotherapy has been high, but patients regularly relapse with a median overall survival of approximately 1 year.

Is BPDCN a myeloid malignancy?

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare myeloid malignancy with no defined standard of care. BPDCN presents most commonly with skin lesions with or without extramedullary organ involvement before leukemic dissemination.

How do you treat BPDCN?

Treatment for BPDCN begins with chemotherapy or targeted therapy, sometimes followed by a stem cell transplant. Some patients participate in a clinical trial exploring new treatments for BPDCN, either as their first treatment or later in their treatment journey.

What is blastic leukemia?

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare type of acute leukemia that impacts about 500-1,000 people in the U.S. each year. It mainly affects older patients, but can affect people of any age.

What kind of blood cancer is BPDCN?

Blastic plasmacytoid dendritic cell neoplasm, or BPDCN, is a rare, aggressive blood cancer, with features of both lymphoma and leukemia.

What is Blastic plasmacytoid dendritic cell neoplasm ( BPDCN )?

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), previously known as natural killer (NK) cell leukemia/lymphoma, is categorized by the World Health Organization (4th edition, 2008) under acute myeloid leukemia (AML).

Are there more men than women with BPDCN?

There are more men than women who are diagnosed with BPDCN. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is very often misdiagnosed and under-reported. Diagnosing a patient with BPDCN is difficult. The skin is the most frequently involved site of disease (80 percent of cases).

Is the leukemic phase of BPDCN common?

A leukemic phase of the disease is a common feature of end stage and post-therapy relapsing BPDCN.